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Intercalationncreasing concentrations of thrombin produced large amounts of phosphatidic acid
(PA) and distinct changes in phosphatidylinositol-4-phosphate (PIP) and phosphatidylinositol-4,5-bisphosphate
(PIP2), prominent metabolites in the polyphosphoinositide (PPI) cycle. The relation between normalized PA and
PIP orPIP2 levels in such thrombin-treatedplatelets from22normaldonors gave avery similar pattern, suggesting
tight control of the metabolites in the polyphosphoinositide (PPI) cycle. Prochlorperazine (PCP), triﬂuoperazine
(TFP), haloperidol (HPD), quetiapine (QTP), pimozide (PMZ) and clozapine (CLO) interfered with this tight
coupling produced by treating platelets with increasing thrombin concentrations. All drugs decreased the
formation of PA at a given thrombin concentration, a decrease that varied greatly among platelets from different
donors. Thismade it difﬁcult to treat the PIP/PA and PIP2/PA relationshipswith ordinary, descriptive statistics. The
data were therefore subjected to regression analysis using polynomials of second or ﬁrst degree and gave the
interference rankingorder: PCPNTFP≫PMZ=HPDNCLONQTP. All six drugs increased themeanmolecular area of
monolayers of dipalmitoyl phosphatidylserine on pure water at 37 °C by 20–50%, while they had little effect on
monolayers of dipalmitoyl phosphatidylcholine. These results suggest that the drugs are membrane-active and
may intercalate in biomembranes containing negatively charged phospholipids. Since human platelets do not
contain D2 receptors, the interferencewith the tight coupling of PPI cyclemetaboliteswas not receptor-mediated.
We suggest that the drugs are intercalated in the plasma membrane and alter the relative, spatial positioning of
phospholipid-consuming enzymes and thereby alter the velocities of the enzyme-catalyzed reactions. Such
intercalation could be part of the side effects of the drugs and may explain their psychotropic action(s).
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe polyphosphoinositide cycle is a major signalling device in
humanplatelets that is stimulated bymost physiological agonists [1,2].
Themetabolites of the PPI cycle in anucleate cells, such as platelets, are
contained in the plasma membrane (PM) and exclusively in the inner
leaﬂet, as shown in the Fig. 1. The inositol moiety of the inositol lipids
sticks out in the cytosol togetherwith the (diester) phosphate and part
of the glycerol moiety. The two acyl groups, usually stearoyl in the sn-1
position and arachidonoyl in the sn-2 position, are deeply and ﬁrmly
situated in the hydrophobic part of the leaﬂet.e; DMSO, dimethylsulfoxide;
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l rights reserved.The cycle starts with the phosphorylation of the 4-hydroxyl group
of PI by ATP catalyzed by PI 4-kinase (enzyme A) and forming PIP. This
phosphate, however, is split off by a phosphohydrolase (enzyme B).
PIP is in turn phosphorylated in the 5-position by ATP with the en-
zyme C, thus forming PIP2, and this 5-phosphate is also split off by a
phosphohydrolase (enzyme D). Thus, both PIP and PIP2 exist in the cell
as typical steady-state levels and their monoester phosphate groups
have high turnover [3]. This is the reasonwhy these phosphate groups
become heavily labelled when the cells are incubated with [32P]Pi
making the γ-phosphoryl group in ATP radioactive.
The whole PPI cycle turns over slowly in non-stimulated platelets,
and this turnover increases 20–30 fold when the cells are stimulated
with thrombin [4], which stimulates phospholipase C-β (PLC, enzyme E)
in platelets. Phospholipase C (PLC) hydrolyses irreversibly the diester
phosphate bond in PIP2 thus forming IP3 andDAG, the former ofwhich is
released to the cytosol where it mobilises Ca2+ from the endoplasmic
reticulum; IP3 is rapidly dephosphorylated in cytosol to free inositol,
which is used later in the PPI cycle (broken line Fig. 1). Diacylglycerol
(DAG), on the other hand, remains ﬁrmly attached to the PM and is
rapidly phosphorylated by ATP to PA with DAG kinase (enzyme F).
Phosphatidic acid (PA) may be rapidly dephosphorylated by PA
Fig.1. The polyphosphoinositide cycle. All metabolites are present in the inner leaﬂet of the plasmamembrane and the border between the lipophilic part of this leaﬂet and cytosol is shownwith the thick, grey line. The formulas are drawnwith
near to correct C–C distances and angles. The metabolites are: PI = phosphatidylinositol, PIP = phosphatidylinositol-4-phosphate, PIP2 = phosphatidylinositol-4,5-bisphosphate, DAG = diacylglycerol, PA = phosphatidic acid, CDPDAG = cytidine
diphosphodiacylglycerol, CMP = cytidine monophosphate, CTP = cytidine triphosphate, IP3 = inositol 1,4,5-trisphosphate. Pi = inorganic orthophosphate, PPi = inorganic pyrophosphate. The enzymes are: A=PI 4-kinase, B=PIP 4-
phosphohydrolase, C=PIP 5-kinase, D=PIP2 5-phosphohydrolase, E=PI-speciﬁc phospholipase C, F=DAG kinase, G=PA phosphohydrolase, H=CTP phosphatidate cytidylyl transferase, I=PI synthase (or: CDP-diacylglycerol-inositol
phosphatidyl transferase).
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phohydrolase is localized in such a way that it can act on the PA formed
by DAG kinase. PA is certainly processed by CTP: phosphatidate cytidylyl
transferase (enzyme H), which transfers a CMP moiety from CTP to PA,
forming CDPDAG and PPi, the latter of which is continuously hydrolysed
to Pi, thus making the formation of CDPDAG (and removal of PA)
irreversible. The CDPDAG is ﬁnally converted to PI by PI synthase
(enzyme I) utilizing the freemyo–inositol formed in the cytosol from IP3.
The formation of CDPDAG in thrombin-stimulated platelets is 30–
40 times slower than the formation of PA [4], such that PA
accumulates. The concentration of DAG is small and transient, which
has made us use PA accumulation as a measure for the PLC activity.
The metabolites we have measured in the present work PI, PIP, PIP2
and PA, are all present in PM, and thus are typical PM-bound sub-
strates and products. These metabolites are strictly organised in a
three-dimensional dynamic structure inside the inner leaﬂet of PM.
Their positioning is optimised for at least six enzymes (A–F) that
control their levels. It is reasonable to assume that these levels are
mainly controlled by the enzymes A–F, but the rates of these reactions
catalyzed by these phospholipid-converting enzymes (soluble or
membrane-bound) are all dependent on the positioning of their
substrates, the so-called substrate availability [5].
Phosphatidic acid is also formed by the phospholipase D (PLD)
reaction. Human platelets contain PLD isoforms 1 and 2 that are sti-
mulated by thrombin [6]. However, the main substrate for PLD is
phosphatidylcholine, which is not labelled by [32P]Pi under the con-
ditions used in the present work [7]. Thus, the 32P-labelled PA formed
during thrombin action on [32P]Pi-labelled platelets originates solely
from the PLC-DAGK reaction.
Chlorpromazine (CPZ), a cationic, amphiphilic phenothiazine, has
been used as an antipsychotic drug that acts as a dopaminergic receptor
antagonist [8]. However, in therapeutic concentrations CPZ affectsmany
other cellular responses, including inhibition ofmitosis and interference
with DNA structure (for references, see Ref. [9]). Chlorpromazine
protection of red cell haemolysis (“membrane stabilization”) is depen-
dent on membrane linoleate [10]. Chlorpromazine also affects voltage-
dependentNa+ currents [11] aswell asATP-sensitive K+ channels [12,13].
The phenothiazines are also known to be calmodulin antagonists (for
references, see Ref. [14]), CPZ increases cholineuptake across the plasma
membranes of myocytes [15] and interferes with platelet polypho-
sphoinositide metabolism [16].
These effects of CPZ on various processes all take place in biological
membranes, which has prompted physicochemical studies of the
interaction between CPZ and glycerophospholipids. Chlorpromazine
has been shown to bind to biological and artiﬁcial membranes with
both high and low afﬁnity; the high afﬁnity binding is caused by
simple partitioning and the variation in KD may be explained by the
ﬁndings that CPZ forms tight 1:1 complexes with the acidic phos-
pholipids like phosphatidic acid (PA) and phosphatidylinositol (PI) but
not with neutral glycerophospholipids such as phosphatidylcholine
(PC) [17–19]. The difference in the interaction of CPZ with acidic and
neutral phospholipids has also been established in our laboratory [20].
Above 30–40 μM triﬂuoperazine (TFP) [21], CPZ [22], and other
phenothiazines or tricyclic antidepressants [23] cause leakage of low
molecular weight cytoplasmic substances, such as adenine nucleotides
and glycolytic intermediates from human platelets, but not of lactate
dehydrogenase, a large, high molecular weight enzyme [22]. Loss of
essential cytoplasmic components could be responsible for the
inhibitory effects reported in numerous studies in which drug con-
centrations ranging from 50–2000 μM have been used (see Refs. [3–15]
in Ref. [23]). Below 30–40 μMCPZ exerts two effects: 1) below 10–15 μM
it stimulates thrombin-induced dense granule secretion and PA pro-
duction in human platelets and 2) at 15–30 μM it inhibits these effects
[23]. Human platelets do not have D2 receptors [24] that are considered
to be the target for CPZ [8]. The stimulatory and inhibitory effects of the
drug can therefore not be due to D2 antagonism, but may be due to theability of CPZ to interact with acidic glycerophospholipids as noted
above. This interaction has been strongly supported by our solid-state
31P- and 13C-NMR investigations [25–27].
The most striking cellular effects observed up to now of CPZ
below 30–40 μM are its stimulation [16] and inhibition [23] of the
polyphosphoinositide (PPI) cycle in platelets, a property also shared
by TFP [28]. There is a tight coupling between the relative levels
of phosphatidylinositol-4-phosphate (PIP), phosphatidylinositol-
4,5-bisphosphate (PIP2) and phosphatidic acid (PA) in thrombin-
stimulated platelets in that a given increment in the PA concentra-
tion is coupled to distinct changes in the concentrations of PIP and
PIP2 [29]. This tight coupling is, however, markedly altered by CPZ
[30], an effect that we believe is not caused by direct interaction of
CPZ with the many enzymes in the PPI cycle. We envision rather
that it is caused by the structural changes in the plasmamembrane that
will alter the relative positioning of glycerophospholipid substrates to
the enzymes in the PPI cycle. Thus, the “substrate availability” for the
enzymes is altered and results in inhibition or activation of the reactions
catalyzed by the enzymes acting on themembrane-localized substrates
[27].
In the present paper we have investigated whether two other
phenothiazines, TFP and prochlorperazine (PCP), and four atypical
psychotropic drugs share the same property as CPZ in altering the
tight coupling of metabolites in the polyphosphoinositide PPI cycle in
human platelets. The atypical drugs are haloperidol (HPD), pimozide
(PMZ), clozapine (CLO) and quetiapine (QTP), the formulas of which
are shown in Scheme 1 together with those of CPZ and TFP.
2. Materials and methods
2.1. Chemicals
Chlorpromazine (CPZ) and triﬂuoperazine (TFP), were obtained from Sigma (St.
Louis, MO). Haloperidol (HPD) and pimozide (PMZ) were from Janssen Foundation
(Berse, Belgium), quetiapine (QTP) was from AstraZeneka (UK Ltd., Macclesﬁeld, UK),
prochlorperazine (PCP) was from Rhone-Poulenc Pharma Norden (Oslo, Norway), and
clozapine (CLO) was from Alpharma AS (Oslo, Norway).
[32P]Orthophosphate (phosphorus-32 PBS 11, carrier-free) was from Amersham
Pharmacia Biotech (Buckinghamshire, UK). Thrombin (bovine) was from Parke-Davis
(Scarborough, ON, Canada) and stored in small portions of 100 U/ml 0.15 M NaCl at
−20 °C; appropriate dilutions in 0.15MNaClweremade before each experiment and the
remaining stock portion was discarded.
Prochlorperazine, TFP and QTP were dissolved in 0.15 M NaCl, the stock solutions
were stored in the dark at −20 °C and dilutions were made with 0.15 M NaCl just before
use. Clozapine and PMZ were dissolved in DMSO and the stock solutions were stored in
the dark at −20 °C. Dilutions were made with 0.15 M NaCl (CLO) or a Tyrode's solution
containing 0.2% albumin (PMZ) just prior to use. Haloperidol was provided in 0.2% lactic
acid and stored at −20 °C in the dark; dilutions were made with 0.15 M NaCl.
2.2. Blood
Blood was obtained from the blood bank, Haukeland University Hospital, Bergen,
anticoagulated with acid citrate dextrose (“ACD”, 85 mM trisodium citrate, 71 mM citric
acid, 111 mM dextrose; 1 volume+4 volumes of blood), being collected from regular
blood donors and from haemochromatosis patients who claimed not to have taken any
medications 10 days prior to blood donation. We used blood from this patient group
because therapeutic phlebotomy results in it being abundantly available to us. In our
hands platelets from haemochromatosis patients and normal donors were the same
with respect to thrombin-induced shape change, aggregation, secretion of ATP+ADP
and PPI metabolism in resting and thrombin-stimulated cells (unpublished results), and
we have not found any literature reports to the contrary. In the experiments reported
here platelets from haemochromatosis patients and normal donors were used
interchangeably.
2.3 32P-labelled platelets in GFP
Platelets used in this study were incubated in autologous plasma with [32P]Pi and
transferred to a phosphate-free Tyrode's solution by gel-ﬁltration (see theMaterials and
methods section). Using this procedure the metabolically active pool of ATP is labelled
to a certain speciﬁc radioactivity, different from donor to donor, and excess, non-
incorporated [32P]Pi is removed. In the GFP so prepared the speciﬁc radioactivity of ATP
in the platelets remains constant for at least 90min [3] due to the lack of non-labelled Pi
in the Tyrode's solution. The radioactivity in PA, PIP and PIP2 ([32P]PA, [32P]PIP and [32P]
PIP2, respectively), which we have measured in this work, is a relative measure of the
Scheme 1. Structural formulas of the drugs studied. The formula of chlorpromazine is shown for comparison.
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the diester phosphate between the glycerol and inositol moieties of PI is not in isotopic
equilibrium with ATP [31] and changes in [32P]PI are not considered in this study.
Therefore, the pixel-values of PA, PIP and PIP2 represent the levels of [32P]PA, [32P]
PIP and [32P]PIP2, respectively, which are expressed in percent pixels of their values in
the NaCl-control (see Fig. 3). The effect of incubation time (0–120 s) on the changes in
PA, PIP and PIP2 was studied for all drugs at 30 μM and 0.3 U/ml of thrombin, and
maximal changes were produced at 90 s; throughout the 120 s of incubation without
thrombin, all drugs caused a 5–15% increase in the PIP level in control platelets not
treated with thrombin (data not shown).
2.4. Expression of data
The Instant Imager expresses the relative radioactivity as pixels. The pixel-values
for PIP2, PIP and PA in the control sample, that is GFP incubated without addition of
thrombin or drug (NaCl-control) was set to 100, and the pixel-values in the same
metabolites in the GFP samples incubated with thrombin with or without drugs were
expressed relative to this value.
2.5. Preparation of [32P] orthophosphate-labelled, gel-ﬁltered platelets (GFP)
Concentrated platelet-rich plasma was prepared from the blood as described
elsewhere [32] and incubated with 0.1 mCi [32P]orthophosphate/ml at 37 °C for 1 h and
then transferred by gel-ﬁltration into Tyrode's solution without phosphate and calciumbut containing 0.2% bovine albumin and 5 mM glucose as described in detail elsewhere
[33]. The platelet count in the radioactive GFP was adjusted to 3.5×108 cells/ml and the
GFP was immediately used in the experiments.
2.6. Incubations
Aliquots (in duplicate) of 500 μl the [32P]Pi-labelled GFP were pre-equilibrated at
37 °C for 1 min, then 50 μl of drug solution (at the concentrations stated in the ﬁgure
legends) or 0.15 M NaCl (control) was added, followed 90 s later by 50 μl of thrombin at
the ﬁnal concentrations indicated in the ﬁgure legends. These mixtures were incubated
at 37 °C for the times stated and 500 μl aliquots were transferred to 2.0 ml of ice-cold
chloroform/methanol/HCl (40:20:1), followed by phase separation and the chloroform
phases were evaporated as described elsewhere [34]. The dried lipid extract was
dissolved in 40 μl chloroform, applied onto silica thin-layer plates (Silicagel 60,
Aluminium, Merck, Darmstadt, Germany) and chromatographed for 90 min with
chloroform/methanol/20% methylamine in water (60:36:10) at room temperature [32].
The radioactive spots were detected and quantiﬁed with a Packard Instant Imager
(Meriden, CT).
2.7. Langmuir monolayer experiments
The experiments were carried out with a KSV Minitrough (Helsinki, Finland) with
MilliQ water as the subphase and the calculation of percent change in mean molecular
area at surface pressures (Π) of 10, 20 and 30 mN/m for the drug-containing sample
Table 1
Relative differences and ranking order of the drugs' interference with the tight coupling
of PPI metabolites
Description PCP TFP QTP HPD PMZ CLO
1. Mean relative differences,
mean(DPIP)
0.68 0.55 0.02 0.21 0.23 0.24
2. Mean relative differences,
mean(DPIP2)
−0.31 −0.25 −0.11 0.24 −0.13 0.02
3. Ranking order for PIP 6 5 1 2 3 4
4. Ranking order for PIP2 6 5 2 4 3 1
5. p-values t-test, H0:mean(DPIP)=0 0 0 0.11 0.0002 0 0
6. p-values t-test, H0:mean(DPIP2)=0 0 0 0 0.035 0 0.626
7. Mean ranking order 6 5 1.5 3 3 2.5
The experiments exempliﬁed with platelets from one donor, but different donor for
each drug in Fig. 5. The experiments were repeated with platelets from 2more different
donors for each drug. The data from platelets from altogether 3 donors for each drug
were analyzed by regression using polynomials of second degree, as explained in the
Materials and methods section.
2169R. Oruch et al. / Biochimica et Biophysica Acta 1778 (2008) 2165–2176relative to that of the corresponding area in the control without drug at the same
surface pressures was performed as described by Broniec et al. [35].
2.8. Statistics
Descriptive statistics were used for the data in panels II in Fig. 4A and B, showing
mean values and standard errors of the relations between [32P]PA and [32P]PIP or [32P]Fig. 2. Effects of the concentrations of prochlorperazine and quetiapine on the changes
in PA, PIP and PIP2 during incubation of GFP in the absence and presence of thrombin.
Samples of 32P-labelled GFP were incubated at 37 °C with the indicated concentrations
of the drugs with (open symbols) or without (closed symbols) 0.3 U/ml of thrombin. The
drugs were incubated in GFP at 37 °C for 90 s before addition of thrombin or NaCl.
Ninety seconds after thrombin addition the reactions were stopped by mixing the
samples with ice-cold CHCl3/CH3OH. The phospholipids were extracted and separated
and their radioactivities quantiﬁed as pixel-values as described in the Materials and
methods section. The percent changes in [32P]PA (◊,O), [32P]PIP (○,●) and [32P]PIP2
(▽,▼) relative to the respective metabolites in the sample without drugs (0 μM) or
thrombin (NaCl-control) are shown.PIP2 and in platelets from altogether 22 donors treated with thrombin in the absence of
any drug.
The two panels labelled I in Fig. 4A and B show the raw data from one of the
experiments where each curve point represents a thrombin concentration. It is clear that
the initial (0U/mlof thrombin) andmaximal (0.3U/ml of thrombin)pixel-values of [32P]PA,
[32P]PIP and [32P]PIP2 variedwidely among platelets from the 3 donors both in the absence
and presence of drug. Moreover, since the data points on the drug curve did not lie
verticallyover thoseof the control curve,descriptive statistics couldnotbeused to calculate
p-values. Therefore, regression analysis using polynomials of second degree was used.
2.9. Regression analysis
The apparent non-linear data (obtained when treating the platelets with increasing
doses of thrombin for 90 s in the absence and presence of 30 μM drug with platelets
from 3 different donors, as shown in panels I in Fig. 4A and B) were subjected to
regression analysis using polynomials of second degree (i.e., p(x)=ax2 +bx+c) by the
least squaresmethod. The aim of the analysis was to determinewhether the response of
the untreated samples was different from that of the treated samples, i.e. we wanted to
estimate whether one of the two responses was signiﬁcantly above or below the other.
The choice of a higher order polynomial instead of a linear polynomial was because we
assumed that the relationships between PA and PIP or PIP2 were expected to be curved.
(Exempliﬁed in panels I in Fig. 4A and B). This manner of action allowed a more fair
treatment of curved data (if the data were truly linear, the second degree polynomial
would be reduced to a linear polynomial). Speciﬁcally for each drug, one pair of
regression curves pm (treated samples) and pc (untreated samples) was constructed for
each of the three donors and for PIP and PIP2.
The curves showing the mean between the three donors for each drug are plotted
in Fig. 5. Due to the non-evenly spaced PA-values between the donors' platelets, each
donor was chosen to serve as its own control. As a consequence of this, the minimum
andmaximumvalues of PA for both treated and untreated samples were scaled to 0 and
1, respectively, and relative differences between the untreated and drug-treated sam-
ples for each donor i were calculated by estimating the relative difference di xj
 
=
pic xjð Þ−pim xjð Þ
pic xjð Þ for six evenly spaced points j={1…6} on the regression curves and for the
three donors i={1…3}. Exactly six points were chosen for each donor to match the
original problem of six data points. Thus, a vector di was constructed for each donor i,Fig. 3. Effects of increasing thrombin concentrations on the relation between radio-
active PIP, PIP2 and PA in platelets not incubated with drugs. Samples of 32P-labelled
GFP were incubated without drugs and increasing concentrations of thrombin (0.0,
0.03, 0.05, 0.08, 0.10, 0.3 U/ml, ﬁnal concentration) for 90 s, after which the reactions
were stopped by mixing the samples with ice-cold CHCl3/CH3OH. The mixtures were
then treated further as explained in Fig. 2. The percent increment in [32P]PA relative to
the control without thrombin is shown on the abscissa and the percent increase in
[32P]PIP ( ) and [32P]PIP2 (——) is shown on the ordinates. The data represent
averages and standard errors from experiments with platelets from 22 different
donors. The vertical bars represent standard errors for [32P]PIP or [32P]PIP2, while the
horizontal bars represent standard errors for [32P]PA.
2170 R. Oruch et al. / Biochimica et Biophysica Acta 1778 (2008) 2165–2176reﬂecting the difference between the untreated and treated sample. Note that a
situation where the two curves are almost equal piccp
i
m
 
or a situation where they are
equally much above or below each other will imply Di =
P6
j = 1
di xj
 
c0. Therefore, the
hypothesis test comparing a single sample mean to zero was conducted to test whether
pc was signiﬁcantly above or below pm for the three donors. Deﬁne D=[D1, D2, D3],
containing the data from all three donors, and the hypothesis
H0: D̄=0
H1: D̄≠0;
was tested on a signiﬁcance level αb0.05. H1 corresponds to a situation where pc differs
frompm such that one of them ismainly above or below theother. Thep-values obtained are
listed in rows5 and6 inTable 1. Thep-values arebelow0.05 and D̄̄was therefore signiﬁcantly
different from zero except for QTP (PIP), HPD (PIP2) and CLO (PIP2). D̄̄was used to obtain a
degreeof interference, and theobtainedmeanvaluesarepresented in rows1and2of Table1.
Note that H0 implies D̄≈0 and larger interferences of the drug produce correspondingly
larger |D̄̄|. Based on these means, a ranking order was made to rank the drugs according to
their inﬂuence. The ranking is shown in rows 3 and 4 of Table 1, where the highest ranking
number is a drug with the highest impact on the tight control of PPI metabolites.
3. Results
3.1. Introductory studies in order to determine the drug concentration
and incubation time causing maximal effect on PPI metabolism
Fig. 2 illustrates the effects of increasing concentrations of PCP and
QTP on the percent changes, relative to the NaCl-control, in the pixel-Fig. 4. Effects of prochlorperazine on the tight coupling of PPI cyclemetabolites inplatelets from
of 32Pi-labelled GFP from three different donors were incubated with and without (control) 3
ﬁnal concentration) for 90 s at 37 °C, afterwhich the reactionswere stoppedand the samples tr
pixel-values (proportional with the radioactivity) of PA, PIP and PIP2 determined in an Instant
for PIP and PA. Panel I: Raw pixel-values from platelets from each of the 3 donors. Diamonds,
open symbols represent incubation with and without PCP, respectively. Panel II: The data fro
abscissa while the percent changes in the [32P]PIP values are shown on the ordinates. The pe
means (±SE) of experiments with platelets from the three different donorswhere the horizon
PA. Panels I and II: Same explanations as above, but with pixel-values for PIP2 instead of PIPvalues of PA, PIP and PIP2 in 32Pi-labelled GFP treated with 0.3 U/ml of
thrombin for 90 s. The changes were similar, but much greater for PCP
than for QTP (Fig. 2). Common for these two drugs, and also for the
other four studied (results not shown), was that they increased the PIP
level to different extents but did not alter the PA levels in non-
stimulated platelets. In contrast, when the cells were stimulated by
thrombin, PA increased 3000–4000% in the absence of drugs as is seen
in Fig. 2 at 0 μM drug. This increase was markedly enhanced by
increasing drug concentrations, although to different degrees and
concentration dependence for each drug. In general, all drugs, except
HPD, increased the PIP level and decreased the PIP2 level in thrombin-
stimulated platelets, changes that were maximal at 30 μM of the
drugs.
Similar assays were done for the other 4 drugs and all caused the
greatest changes at 30 μM (data not shown).
3.2. Effects on the levels of PA, PIP and PIP2 in platelets incubated in the
absence of drugs with increasing concentrations of thrombin
From the drug dose–response and time course studies above we
decided to study the effects of varying the thrombin concentration at
30 μM of the drugs and an incubation time of 90 s. In our previous
work [29] the plots of the percent increment in PIP and PIP2 against
the percent increments in PA induced by increasing concentrations ofthree different donors stimulatedwith increasing concentrations of thrombin. Samples
0 μM PCP and increasing concentrations of thrombin (0.0, 0.03, 0.05, 0.08, 0.10, 0.3 U/ml,
eated further as described in Fig. 2. The sampleswere extracted, separated by TLC and the
Imager. (The thrombin concentration increases from left to right). Fig. 4A shows the data
triangles and circles represent each of the three donors, respectively, and the closed and
m panel I have been treated as in Fig. 3, that is the percent increment in [32P]PA on the
rcent changes refer to the control value without PCP and thrombin. The curve points are
tal and vertical bars represent PA and PIP, respectively. Fig. 4B shows the data for PIP2 and
. Horizontal and vertical bars represent standard errors for PA and PIP2, respectively.
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in the present work platelets from 22 different donors were used. The
relations between PA and PIP or PIP2 from all thrombin-treated
controls (incubated for 90 s without any drugs) from the present
experiments are shown in Fig. 3. As the thrombin concentration was
increased incrementally from 0.0 to 0.3 U/ml, the percent increase in
PA over that in platelets not treated with thrombin (abscissa)
increased by 3300% and the relation between PIP and PA gave a
typical bell-shaped curve while that between PIP2 and PA yielded a
more straightforward relationship that plateaus at higher thrombin
concentrations (Fig. 3). The relative standard errors were considerably
greater for the percent increases in PIP and PIP2 (Fig. 3, vertical error
bars) than in PA (Fig. 3, horizontal error bars), but the differences were
still statistically signiﬁcant. This was probably not due to errors in
measuring radioactivity since the pixel-value for PA increased from
10–20 (control values) to 900–1100 (0.3 U/ml of thrombin) while the
pixel-values of PIP and PIP2 varied from 150 to 400% of these
metabolites in the NaCl-controls (not stimulated with thrombin). The
greater variations in the error bars for PIP and PIP2 than in PA were
therefore probably due to biological variations among platelets from
different donors.
3.3. Effects of incubating platelets with increasing concentrations of
thrombin in the absence and presence of drugs on the relations between
PA and PIP or PIP2
The rate of PA formation and PPI cycle activation in platelets was
proportional to the concentration of thrombin up to the maximally
stimulating dose used, 0.3 U/ml (data not shown). The changes in PIP
and PIP2 with the PA produced by incubating platelets with increasingFig. 5. Effects of PCP, TFP, QTP, HPD PMZ and CLO (30 μM) on the tight coupling of PPI cycl
described in the legend of Fig. 4 and with platelets from one, but different donor for each. Th
the Statistics section. The controls (without drugs) are shown as circles connected with soliconcentrations of thrombin without drugs (Fig. 3) strongly conﬁrmed
our earlier observation [29] that there exists a tight coupling between
the PPI cycle metabolites. Since CPZ greatly disturbed this tight
coupling under identical conditions [30], we investigated whether the
six drugs used in this study also disturbed the tight metabolite
coupling using the same approach as in [30] with platelets from 3
different donors for each drug.
Fig. 4A-I shows the raw data obtained by increasing thrombin
concentrations in the absence (control, open symbols) and
presence (drug, closed symbols) of PCP on the relation between
PA and PIP in platelets from each of three different donors used.
There were great differences in the pixel-values of PA and PIP
among platelets from the 3 donors, both in the absence and
presence of PCP. By normalizing the data (as done in Ref. [30]) by
setting the values for PA, PIP and PIP2, respectively, obtained in the
control sample without thrombin equal to 100 for platelets from each
individual donor and relating all other radioactivities measured to
this value (as done in Figs. 2–3) for each donor, the data can be
presented as mean values with standard error for the 3 donors, as
shown in Fig. 4A-II.
Similarly, Fig. 4B-I shows the raw data for PA and PIP2 from this
experiment and Fig. 4B-II shows the corresponding normalized data.
However, it is clear that the normalized presentation of the rela-
tion between PA and PIP (Fig. 4A-II) or PIP2 (Fig. 4B-II) does not allow
straightforward calculation of signiﬁcance, since the points on the
control curve do not match vertically those on the drug curve. Therefore,
we have treated the data obtained for PCP and the other drugs from
experiments identical to that shown in Fig. 4A and B as explained in
the Statistics section, by regression analysis using polynomials of
second degree.e metabolites in platelets. Data analyzed by regression. The experiments were done as
e data were analyzed by regression using polynomials of second degree as explained in
d lines; the samples with drugs are given as crosses connected with broken lines.
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The results of regression analysis with polynomials of second
degree of the raw data obtained from the experiment with PCP, shown
in panels I in Fig. 4A and B, are presented for each of the three donors
in Fig. 5. It is obvious that in platelets from all three donors PCP
produces large increases and decreases in the pixel-values for PIP and
PIP2, respectively, as compared to the control without the drug at
corresponding normalized PA-values above 0.5. In sharp contrast, QTP
produced far less changes in the relations between PA and PIP or PIP2,
although in the same directions as PCP (Fig. 5).
The results of the statistical treatment of the data obtained for all 6
drugs (each drug tested with platelets from three different donors) are
compiled in Table 1. It can be seen that the mean relative difference
between the drug and control curves for PIP is highly signiﬁcantly
different from zero for all drugs except QTP (row 5). Also the mean
relative differences between the drug and control curves for PIP2 are
highly signiﬁcantly different from zero for all drugs except CLO. All
drugs gave an increase in the pixel-values for PIP, and a decrease in the
PIP2 pixel-values, except for HPD that increased PIP2.
The statistical analysis in Table 1 also gives the mean ranking order
(row 7) for the 6 drugs with respect to what extent (from highestFig. 6. Effects of PCP and CLO on surface pressure-mean molecular area relations of DPPC an
water ( ), 1 μM ( ) or 10 μM (————) PCP or CLO (in MilliQ water) were compressed in th
as explained in Ref. [27]. Clozapine was dissolved in DMSO, and an appropriate amount of DM
drug, and gave identical results; the curves shown are from one of these experiments.to lowest) they interfere with the tight coupling of the PPI cycle
metabolites:
PCPNTFP≫PMZ =HPDNCLONQTP:
The raw data from experiments with all 6 drugs with increasing
thrombin concentrations, as exempliﬁed for PCP in the panels I of
Fig. 4A and B, were also treated statistically by linear regression
analysis (y=ax+b) in a way identical to that used for polynomials of
second degree, and the results obtained gave a mean ranking order of
interference of the drugs with the tight coupling of PPI metabolites
(from greatest to smallest) of: PCPNTFP≫HPD≈PMZNCLO≈QTP, thus
practically the same as the ranking order obtained with the second
order regression analysis.
It should be noted that PCP, TFP, HPD and QTP were water soluble
or could be diluted with 0.15 M NaCl, while PMZ and CLO were only
soluble in DMSO. To test whether DMSO interfered with the para-
meters measured, we incubated control platelets with the usual
concentrations of thrombin in the absence and presence of appro-
priate amounts of DMSO. There was no effect of DMSO on the relation
between PA and PIP or PIP2 in control or thrombin-treated plateletsd DPPS monolayers. Dipalmitoylphosphatidylcholine and DPPS monolayers pure MilliQ
e Langmuir apparatus at 37 °C and the surface pressure measuredwith aWilhelmy plate
SO was included in the control subphase. Three experiments were performed for each
Table 2
Percent change in mean molecular area (mma) relative to control (pure MilliQ water) at
10, 20 and 30mN/m caused by 10 μMCLO, PMZ, PCP, QTP HPD or TFP dissolved in MilliQ
water
Drug PC PS
20 mN/m 10 mN/m 20 mN/m 30 mN/m
CLO 3 36 25 18
PMZ 7 56 42 23
PCP 3 27 20 16
QTP 3 48 27 14
HPD 4 41 30 23
TFP 12 31 27 21
The experiments were performed as described in the legend to Fig. 6, and the percent
change in mma at surface pressures of 10, 20 and 30 mN/mwas calculated. Appropriate
amounts of DMSO were included in controls for PMZ and CLO.
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vent) in the concentrations introduced with HPD were tested in the
same way; and again, there were no effects of lactic acid on the tight
coupling of PPI cycle metabolites (data not shown).
3.3.2. Langmuir isotherms
Surface pressure versus mean molecular area (mma) curves for
DPPC and DPPSmonolayers on distilled water at 37 °C with or without
PCP or CLO in the subphase are shown in Fig. 6. Without any drugs no
changes in surface pressure (Π) of the DPPC monolayer (Fig. 6, left
panels) took place as the mma decreased from 150 Å2 to 120 Å2
showing that DPPC was in the gaseous phase; further decrease in
mma, produced a sharp increase in Π to about 30 mN/m at about
100 Å2 at which point the curve showed a small, but distinct, break
point, and further decrease in mma produced an even sharper
increase in Π until the “collapse point” at 50 mN/m and 95 mma
after which Π remained constant by further compression of DPPC.
(One believes that the monolayer collapses by folding over itself).
During the sharp increase in Π between 120 mma (so-called “lift-off”
point) and collapse the glycerophospholipid is thought to go through
the liquid-to-solid state). For pure DPPS (Fig. 6, right panels) the Π/
mma isotherm resembled that of DPPC, except that lift-off took place
at about 100 Å2 and the isotherm had no breakpoint in the liquid-to-
solid phases.
Both PCP and CLO drastically altered the DPPS isotherm (Fig. 6,
right panels), but had little effect on the DPPC isotherm (Fig. 6, left
panels). It is seen that in DPPSmonolayers both PCP and CLO increased
the mma at all Π levels and also lowered the surface pressure at the
collapse point to a certain extent. We tested the effects of 1 and 10 μM
HPD, TFP, QTP and PMZ on DPPC and DPPS monolayers under exactly
the same conditions as used in Fig. 6 and obtained very similar results,
i.e., hardly any effects on DPPC isotherms and large increases in the
mma at all Π for DPPS. Some quantitative results taken from these
isotherms and from those in Fig. 6 are shown in Table 2. The increases
(in percent) by 10 μM of the drugs in mma at 10, 20 and 30 mN/m
relative to the correspondingΠ in the control isotherms are shown in
Table 2. This table also shows the corresponding changes caused in
DPPC and DPPS monolayers caused by the other drugs studied herein,
TFP, QTP, HPD, and PMZ. Table 2 shows clearly that all 6 drugs have
little effect on the DPPC isotherm, while they markedly increased the
mma at 10, 20 and 30 mN/m of the PPS isotherm.
4. Discussion
The main aim of this study was to investigate whether two typical
(PCP, TFP) and four atypical (CLO, HPD, PMZ, QTP) psychotropic drugs
affected the tight coupling of PPI cycle metabolites in thrombin-
stimulated human platelets in the same way we have previously
shown for CPZ [30]. Our experiments on the effects of drug con-
centrations (Fig. 2) and incubation time (data not shown) on the levelsof platelet PA, PIP and PIP2 in the absence and presence of drugs
showed several important differences among the drugs that are under
further studies in our laboratory and may reveal speciﬁc stages in the
cycle where the drugs act. In the present study the optimal drug
concentration of 30 μM and incubation time of 90 s were found to give
maximal drug effects in the experimental system used. For the
comparative study we employed many thrombin concentrations
(Figs. 3 and 4) in order to vary the metabolites in the PPI cycle to
different degrees in the absence and presence of the drugs. This
approach enabled us to ﬁnd certain thrombin concentrations (re-
corded as degree of PA production) where the drugs induced sig-
niﬁcant relative differences between PA and PIP or PIP2. With a ﬁxed
thrombin concentration these signiﬁcant differences may have been
missed.
We have strongly conﬁrmed our earlier observation [29] that there
exists a tight coupling between the levels of PA, PIP and PIP2 in platelets
stimulated with increasing concentrations of thrombin (Fig. 3). The six
psychotropic drugs studied interfered strongly, but to different degrees
with this coupling (Figs. 4 and 5). As explained in the Introduction, the
levels of eachof thesemetabolites are controlled by several enzymes, both
membrane-bound and cytosolic. Thus, [PIP] is controlled by PI 4-kinase,
PIP 4-phosphohydrolase, PIP 5-kinase and PIP2 5-phosphohydrolase,
while [PIP2] is maintained by PIP 5-kinase, PIP2 5-phosphohydrolase and
Phospholipase C, which is strongly stimulated by thrombin, and [PA] is
mainly controlled by diacylglycerol kinase and PA phosphohydrolase.
Moreover, these PPI metabolites are imbedded in the cytosolic leaﬂet of
the platelet plasmamembrane and as substrates for the enzymes they are
structured. The conventional way of testing metabolic effects of drugs on
each of pure PPI cycle enzymes in reconstituted systems would be non-
physiological and the results obtained were subject to very difﬁcult
interpretations. Therefore, we have measured the PPI cycle metabolite
level in the intact platelets with a physiological membrane and enzymes
present in their biological environment.
The psychotropic drugs perturbed the tight control of PPI cycle
metabolites in platelets to different degrees as evidenced by the
signiﬁcant displacements of the relations between PA and PIP or PIP2
in Fig. 5, and by the mean differences in Table 1. The same raw data
used for Fig. 5 were subjected to regression analysis using polynomials
of second (Table 1) and ﬁrst degree (see text), respectively. Both the
two regression analyses gave practically the same ranking order for
the disturbance of the tight coupling of PPI cycle metabolites. How-
ever, the regression analyses did not discern what degree of stimulus
(i.e. thrombin concentration) gave signiﬁcant disturbance of the tight
coupling of PPI cycle metabolites between the presence and absence
of drugs. The Tyrode's solution used to make GFP contained 0.2%
albumin, which is likely to bind the amphiphilic drugs studied.
Binding of HPD [36,37]; TFP [38] and CLO [39] has been reported,
although exact partition coefﬁcients were not measured. The binding
of the six drugs studied may vary, which may inﬂuence the ranking
order for interference with the coupling of PPI metabolites shown in
Table 1.
Since platelets do not have D2 receptors [24], the supposed main
targets for psychotropic drugs, the disturbance of the tight coupling of
PPI cyclemetabolites is not due to receptor antagonism, but could be due
to intercalation of the amphiphilic drugs in the platelet plasma mem-
brane, which is discussed below. We have used intact platelets as a
model of a cell that responds to stimuli (such as thrombin) with a
marked activation of PIP2-speciﬁc phospholipase C and, hence,
increased turnover of the PPI cycle. Most stimulatable cells, including
neurons [40], have a well-developed PPI cycle, which controls central
cellular activities such as signalling, membrane trafﬁcking [41], nuclear
processes [42] and cytoskeleton remodelling [41], as well as being
implicated in several humandiseases [43].Most importantly, our studies
were done with intact cells in which the organisation of phospholipid
intermediates in the PPI cycle is in the native state. We feel, therefore,
that the ﬁndings reported here may reﬂect the perturbation of PPI
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pathways for cellular activities.
Our monolayer experiments showed that all six drugs had little
effect on the isotherms of DPPC, a neutral phospholipid, while they
markedly increased the mma at all surface tensions after lift-off of
DPPS, a negatively charged phospholipid. This behaviour is exactly the
same as we have earlier found for CPZ [20], and which we have
interpreted as intercalation of the cationic drug among the negatively
charged PS molecules. The six drugs tested here also have ionizable
amine groups (Scheme 1) and, since the pH of the MilliQ water used is
about 6, the drugs would be positively charged and probably interact,
like CPZ [25] with PS with both electrostatic and hydrophobic forces.
A comparison between the effect of the drugs on the tight coupling
of PPI cycle metabolites (Table 1) and on the increase in mma of the PS
monolayers (Table 2) clearly shows that these phenomena are not well
correlated. However, we intended to perform the monolayer experi-
ments under conditions that maximised the intercalation effects by
the drugs, that is use of MilliQ water with very low ionic strength in
the subphase, since monovalent cations counteract the mma-in-
creasing effects of CPZ [20]. The platelet experiments were done with
the cells in Tyrode's solution, containing 0.15 M NaCl and 0.2% al-
bumin. The counteracting effects of Na+ on increasing the mma may
therefore be very different for the six drugs studied. Furthermore, in
an intact cell the drugs are exposed to mixtures of phospholipid
classes and molecular species, while we have only studied one PS
species, namely DPPS. The purpose of our monolayer studies here was
simply to show that all drugs studied have potential membrane-
interacting properties.
4.1. Effects of the psychotropic drugs on the coupling of PPI cycle
metabolites and their possible biological mechanism(s)
The two phenothiazines PCP and TFP interfered the most with the
tight coupling of PPI cycle metabolites while QTP interfered the least.
The latter drug affected the relations between PA and PIP or PIP2 less
than any of the other drugs and the signiﬁcant fractional changes were
seen over small PA part ranges (Fig. 5). Haloperidol, PMZ and CLO had
intermediate effects on both parameters. Thus, using the integrals of
the fractional changes where pb0.1 for the sum of PIP and PIP2 as a
measure of interference of the tight coupling of PPI cycle metabolites,
the degree of drug impact for all 6 compounds used in this study on
PPI metabolism can be ranked as PCP=TFP⋙zPMZ≈CLONQTP
(Table 1). It is noteworthy that the two phenothiazines studied
showed the greatest interference of the tight coupling of PPI cycle
metabolites and are also generally known to produce much greater
side effects and greater psychotropic effects than the other drugs.
Compared to the other 4 drugs, the two phenothiazines studied
caused greater positive and negative relative differences of the PIP and
PIP2 levels, respectively, a result of increasing the thrombin stimula-
tion and, hence, the PA level (Fig. 5). This change in equilibrium of the
reactions maintaining the PIP2 level suggests that these drugs par-
ticularly suppress the conversion of PIP to PIP2, and that intercalation
of the drugs into the membrane (see below) may make PIP less avail-
able to PIP 5-kinase. The structural formulas of the two phenothia-
zines used here are very similar to that of CPZ (Scheme 1) and these
three phenothiazines may intercalate in a similar way in the mem-
brane. Haloperidol was the only drug that increased the PIP level that
was accompanied by a massive increase in the PIP2 level (Fig. 5). This
compound is structurally very different from the phenothiazines, CLO,
PMZ and QTP (Scheme 1), whichmay reﬂect its different effects on PPI
metabolism in platelets.
Although not shown directly in Fig. 5, but shown for PCP in Fig. 4A
and B, the standard error of means for the percent increase in the PA
levels caused by the drugswere distinctly smaller than those of the PIP
and PIP2 levels. The samewas the case for the control platelets (Fig. 3).
One plausible explanation for this could be that PA accumulates in thecells to levels 30–40 times greater than those in non-stimulated
platelets because of a much faster production by diacylglycerol kinase
than its removal by CTP: PA cytidylyl transferase [4]. In contrast, the
levels of PIP and PIP2 are typical steady-state levels that are the
product of fast phosphorylations and dephosphorylations, as ex-
plained in the Introduction. The drugs did not affect the increase in PA
very much, but did affect the steady-state levels of PIP and PIP2,
suggesting that it is the tight control of these steady-state levels that
was affected.
Except for HPD, the other drugs lowered the PIP2 levels and in-
creased the PIP levels, suggesting direct activation of the PI kinase and/
or inhibition of PIP 5-kinase enzymes by the drugs, although inhibition
of PIP phosphohydrolase and/or activation of PIP2 5-phosphohydrolase
would give the same effect. Activation ofmembrane-bound PI kinase in
intact adrenal chromafﬁn granules by TFP and CPZ has been reported
[44], and the same drugs inhibited puriﬁed, soluble PIP 5-kinase [45].
The same effects of TFP on PI kinase and PIP kinase were found in
cardiac membranes [46]. Interestingly, in the presence of detergent,
the stimulation of PI kinase by TFP was considerably less than for the
membrane-bound enzyme [47], suggesting that intact, biological
membrane organization is important for the effects of the phenothia-
zines. Chlorpromazine has been shown by others [48] to inhibit
thrombin-induced formation of PIP2 and PA in human platelets, thus
conﬁrming our results. Triﬂuoperazine also inhibited phosphorylation
of PIP in membranes from electroplax of Narke japonica [49].
Triﬂuoperazine, but not TFP sulfoxide, activated PI kinase in rat beta-
cell tumour cells [50]; in light of the discussion below it is interesting to
note that the amphiphilic CPZ, but not the non-amphiphilic CPZ
sulfoxide, is intercalated in PS monolayers [20].
In this work we have compared the effects of six psychotropic drugs
on PPI metabolism in platelets, and decided to test this at drug con-
centrations that gave the averagemaximal effects on the PPImetabolites
in platelets treated with increasing concentrations of thrombin (Fig. 5).
The maximal effect for all six drugs was found at 30 μM (with an
incubation time with thrombin of 90 s), a concentration that is con-
siderably higher than the effective serum concentrations (0.1–0.3 μM)
reported in blood of patients during therapy. However, amphiphilic,
psychotropic drugs partition between an aqueous milieu and biological
membraneswithpartition coefﬁcients ranging from850 to 1700 and the
partition depends both on temperature and on the length of the gly-
cerophospholipid acyl chains and their degree of unsaturation [17].
Haloperidol [51–54], PMZ [52,53], CLO [51], TFP [55–59] have been
reported to partition into membranes and alter lateral structure of
biomembranes isolated from a variety of cells and cell organelles. The
partition coefﬁcients vary according to the different methods used and
are in the 500–2000 range.
We have recently shown by solid-state NMR [60] that molecular
species of phosphatidylserine (PS) that contain docosahexenoic acid
form domains in liposomes, and that these domains are perturbed by
CPZ. In addition, the drugs used in the present study are, with the
exception of HPD, strongly positively charged and likely to be at-
tracted to the negative phosphate and carboxyl groups of PS, as we
have shown for CPZ [25]. In addition, we have studied the effects of the
drugs in a closed system where a drug is administered as one single
dose that only undergoes a (one-time) partition between hydrophobic
and hydrophilic compartments. In a therapeutic situation, however,
several doses of drug are administered that would accumulate con-
secutively in membrane compartments in the body, besides being
metabolized. Thus, hydrophobic and electrostatic forces as well as
attraction to polyunsaturated acyl domains in the membranes will
result in a major accumulation of the drugs in themembrane, the local
concentrations of which are not yet known, but which could be very
much higher than the serum concentrations. The present studies
(employing 30 μM drugs in a closed system) may therefore reﬂect real
effects of psychotropic drugs in general on PPI metabolism in target
cells that are involved in the mechanism of their psychotropic action.
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effects of the drugs have never been suggested before, and clearly
represent an issue that should be investigated further and preferably
in neuronal cells.
4.2. Intercalation of cationic, amphiphilic drugs in a bilayer membrane
and its consequences for phospholipid-consuming enzymes and
receptors, using CPZ as a prototype
Our previous physicochemical studies [20,26,27,60,61] have shown
unequivocally that CPZ interacts strongly with negatively charged
glycerophospholipids and poorly with neutral phospholipids. These
lipids are asymmetrically distributed in the plasma membrane with
the neutral phospholipids, PC (up to 70%) and sphingomyelin (25–
30%), mainly in the outer leaﬂet while the inner leaﬂet is composed
mainly of PS, PE, PI, PIP and PIP2. Althoughwe have not studied neutral
sphingomyelin, it is reasonable to assume that it, being neutral like PC,
interacts poorly with CPZ. However, the partition coefﬁcient of CPZ
between hexane and aqueous solutions is in the range of 850–1700
[57], while the partition into liposomes containing PS has a coefﬁcient
in the order of 6.0–6.6×105 [62] and that of many other amphiphilic
drugs may be even higher. Recent NMR studies [60] have shown that
the cationic CPZ binds electrostatically strongly to the phosphate
group and also, but more weakly, to the serine carboxyl group of PS.
Furthermore, at 37 °C CPZ causes a large low-ﬁeld shift of the reso-
nances of the CH2-groups in PC/PS liposomes [26], showing that the
hydrophobic moiety of CPZ becomes intercalated in the acyl chain
domain of the liposomes. Recently it was shown by molecular dyna-
mic simulations that unprotonated CPZ promotes local distortions of
the lipid tails in PC monolayers [63,64]. This lipophilicity makes it
likely that CPZ diffuses across the hydrophobic core of the plasma
membrane and becomes bound to the inner leaﬂet by the negatively
charged PS and PI, and probably more so by the more negatively
charged PIP and PIP2. In this way CPZ molecules will be trapped by the
negatively charged phospholipids, intercalated between them and
accumulate at the inside of the inner leaﬂet and cause large alterations
in its structure. The other positively charged, amphiphilic drugs
described here, may indeed work in a similar way.
Since all six drugs studied interacted with PS monolayers by in-
creasing the mean molecular area, we believe that they intercalate
between the PSmolecules. This intercalationmay also take place in the
platelet plasma membrane and, thus, distorts it which causes changes
in the relative position of lipid-consuming enzymes relative to their
substrates.We propose that this change in substrate availability (a term
introduced to explain the effects of amphiphilic drugs on phosphati-
date phosphohydrolase [5]), for the enzymes by the drugs thus causes
an interference with the tight control of PPI metabolism.
It is important to note that in this proposal, alterations of
enzyme activities are not caused by direct interaction by the
cationic amphiphilic drugs with the enzyme proteins. We propose,
on the contrary, that the drugs cause a change in the plasma
membrane structure that alters the enzyme proteins' access for
their substrates. The alterations in the protein activities are thus
secondary to drug-induced alteration of the membrane structure.
We cannot disregard the idea that the drugs interfere directly with
PPI cycle enzymes, but the levels of the metabolites studied, PIP,
PIP2 and PA, are controlled by 8 enzymes. Further studies and much
more knowledge about the organisation of PPI cycle intermediates
in intact cells are required to pinpoint the details of the actions of
the drugs at the enzyme level.
4.3. Intercalation, partition and drug–membrane interaction
With a ranking order of PCP=TFP≫HPDNPMZ=CLONQTP for the
interference of the tight control of PPI cycle metabolites and our
suggestion that this is caused by intercalation of the drugs in themembrane, one would expect this ranking order to be reﬂected by the
drugs' partition between water and a hydrophobic milieu. Such
partition coefﬁcients are, however, very dependent on the nature of
the hydrophobic milieu. For example, the partition of TFP between
microsomes, liposomes, erythrocyte ghosts or octanol and water has
been reported to be 7172, 1916, 1380 and 452, respectively [65]. Tri-
ﬂuoperazine as a cation binds electrostatically to negatively charged
phospholipids so that binding to microsomes, liposomes and erythro-
cyte ghosts depends on the amount of negatively charged phospho-
lipids, while partitioning into octanol would not include electrostatic
interactions. Partition of HPD and PMZ into membranes made of
various phosphatidylcholines has also been shown to depend on acyl
chain length and unsaturation [65], just aswehave shown for CPZ [20].
Evidently, comparison of partition of amphiphilic drugs between
aqueous and non-polar phases has to be done under strictly identical
polar/non-polar conditions, and we are not aware of published
comparisons among the 6 drugs used in the present study under
such conditions. No effects on humanplatelet aggregation in vitro have
been reported for PCP, QTP, HPD or PMZ. However, CLO increased
platelet aggregation and shortened clotting time [66] while TFP
inhibited aggregation [67,68]. It would therefore be interesting to
establish whether or not these effects, and possible effects of PCP, QTP,
HPD or PMZ, are related to the drugs' effect on the tight coupling of the
PPI cycle metabolites.
In conclusion, the psychotropic drugs tested clearly affected
thrombin-induced PPI metabolism in platelets with the following
ranking order: PCP=TFP≫HPDNPMZ=CLONQTP (almost no effect).
The interference caused by the drugs with the tight control of PPI
cycle metabolites may be part of the mechanisms of the drugs'
psychotropic actions and/or their side effects, and these membrane
effects may represent novel mechanisms that are independent of
receptors. We propose a hypothesis that cationic, amphiphilic drugs
affect the activity of membrane-bound proteins by intercalation
among anionic glycerophospholipids in the inner leaﬂet of the plasma
membrane. The effects of the drugs on the tight coupling of PPI cycle
metabolites reported here strongly support the membrane intercala-
tion hypothesis.
Acknowledgments
This work was partially supported by the Blix foundation, the
Norwegian Research Council and Norwegian Labor Authorities. The
authors wish to thank Sissel Rongved and Ingrid Strand for excellent
technical assistance.
References
[1] A. Ryningen, H. Holmsen, Biochemistry of platelet activation, in: G. Rao (Ed.), Hand-
book of Platelet Physiology and Pharmacology, Norwell, (MA), 1999, pp. 188–237.
[2] L.F. Brass, T.J. Stalker, L. Zhu, D.S. Woulfe, Signal transduction during platelet plug
formation, in: A.D. Michelson (Ed.), Platelets, second edition, Elsevier Academic
Press, Amsterdam, 2007, pp. 319–346.
[3] O.B. Tysnes, A.J. Verhoeven, H. Holmsen, Phosphate turnover of phosphatidylino-
sitol in resting and thrombin-stimulated platelets, Biochim. Biophys. Acta 889
(1986) 183–191.
[4] O.B. Tysnes, A.J. Verhoeven, H. Holmsen, Rates of production and consumption of
phosphatidic acid upon thrombin stimulation of human platelets, Eur. J. Biochem.
FEBS 174 (1988) 75–79.
[5] D.N. Brindley, Intracellular translocation of phosphatidate phosphohydrolase and its
possible role in thecontrol of glycerolipidsynthesis, Prog. LipidRes. 23 (1984) 115–133.
[6] M. Vorland, H. Holmsen, Phospholipase D in human platelets: presence of
isoenzymes and participation of autocrine stimulation during thrombin activation,
Platelets 19 (3) (May 2008) 211–224.
[7] O.B. Tysnes, A.J. Verhoeven, H. Holmsen, Studies on the preferential incorporation
of [3H]glycerol over [32P]phosphate into major phospholipids of human platelets,
Biochim. Biophys. Acta 930 (1987) 338–345.
[8] P. Seeman, Themembrane actions of anesthetics and tranquilizers, Pharmacol. Rev.
24 (1972) 583–655.
[9] T. Lialiaris, A. Pantazaki, E. Sivridis, D. Mourelatos, Chlorpromazine-induced
damage on nucleic acids: a combined cytogenetic and biochemical study, Mutat.
Res. 265 (1992) 155–163.
2176 R. Oruch et al. / Biochimica et Biophysica Acta 1778 (2008) 2165–2176[10] G. Housley, G.V. Born, D.M. Conroy, J. Belin, A.D. Smith, Inﬂuence of dietary lipids
on the effect of chlorpromazine on membrane properties of rabbit red cells, Proc.
R. Soc. Lond., B, 227 (1986) 43–51.
[11] M. Wakamori, M. Kaneda, Y. Oyama, N. Akaike, Effects of chlordiazepoxide,
chlorpromazine, diazepam, diphenylhydantoin, ﬂunitrazepam and haloperidol on
the voltage-dependent sodium current of isolated mammalian brain neurons,
Brain Res. 494 (1989) 374–378.
[12] K. Kon, E. Krause, H. Gogelein, Inhibition of K+ channels by chlorpromazine in rat
ventricular myocytes, J. Pharmacol. Exp. Ther. 271 (1994) 632–637.
[13] M. Muller, J.R. De Weille, M. Lazdunski, Chlorpromazine and related phenothia-
zines inhibit the ATP-sensitive K+ channel, Eur. J. Pharmacol. 198 (1991) 101–104.
[14] M.A. Yacko, D.A. Butterﬁeld, Spin-labeling studies of the conformation of the Ca(2+)-
regulatory protein calmodulin in solution and bound to the membrane skeleton in
erythrocyte ghosts: implications to transmembrane signaling, Biophys. J. 63 (1992)
317–322.
[15] S.W. Rabkin, Effects of chlorpromazine and triﬂuoperazine on choline metabolism
and phosphatidylcholine biosynthesis in cultured chick heart cells under
normoxic and anoxic conditions, Biochem. Pharmacol. 38 (1989) 2349–2355.
[16] K.W. Frolich, G.M. Aarbakke, H. Holmsen, Chlorpromazine increases the turnover
of metabolically active phosphoinositides and elevates the steady-state level of
phosphatidylinositol-4-phosphate in human platelets, Biochem. Pharmacol. 44
(1992) 2013–2020.
[17] M. Luxnat, H.J. Galla, Partition of chlorpromazine into lipid bilayer membranes: the
effect of membrane structure and composition, Biochim. Biophys. Acta 856 (1986)
274–282.
[18] R.A. Schwendener, Incorporation of chlorpromazine into bilayer liposomes for
protection against microsomal metabolism and liver absorption, Eur. J. Drug
Metab. Pharmacokinet. 13 (1988) 135–141.
[19] L. Stuhne-Sekalec, J. Chudzik,N.Z. Stanacev, Effect of chlorpromazine on the synthesis,
hydrolysis, and transfer of microsomal cytidine liponucleotides and mitochondrial
polyglycerophosphatides, Can. J. Physiol. Pharmacol. 65 (1987) 377–384.
[20] A.V. Agasosler, L.M. Tungodden, D. Cejka, E. Bakstad, L.K. Sydnes, H. Holmsen,
Chlorpromazine-induced increase in dipalmitoylphosphatidylserine surface area
in monolayers at room temperature, Biochem. Pharmacol. 61 (2001) 817–825.
[21] H. Holmsen, J.L. Daniel, C.A. Dangelmaier, I. Molish, M. Rigmaiden, J.B. Smith,
Differential effects of triﬂuoperazine on arachidonate liberation, secretion and
myosin phosphorylation in intact platelets, Thromb. Res. 36 (1984) 419–428.
[22] H. Holmsen, T. Rygh, Chlorpromazine makes the platelet plasma membrane
permeable for low-molecular weight substances and reduces ATP production,
Biochem. Pharmacol. 40 (1990) 373–376.
[23] P. Tharmapathy, M.H. Fukami, H. Holmsen, The stimulatory effects of cationic
amphiphilic drugs on human platelets treated with thrombin, Biochem.
Pharmacol. 60 (2000) 1267–1277.
[24] A. Ricci, E. Bronzetti, F. Mannino, F. Mignini, C. Morosetti, S.K. Tayebati, F. Amenta,
Dopamine receptors in human platelets, Naunyn-Schmiedeberg's Arch. Pharma-
col. 363 (2001) 376–382.
[25] S. Chen, A.U. Gjerde, H. Holmsen, W. Nerdal, Importance of polyunsaturated acyl
chains in chlorpromazine interaction with phosphatidylserines: a 13C and 31P
solid-state NMR study, Biophys. Chem. 117 (2005) 101–109.
[26] W. Nerdal, S.A. Gundersen, V. Thorsen, H. Hoiland, H. Holmsen, Chlorpromazine
interaction with glycerophospholipid liposomes studied by magic angle spinning
solid state (13)C-NMR and differential scanning calorimetry, Biochim. Biophys.
Acta 1464 (2000) 165–175.
[27] A. Underhaug Gjerde, H. Holmsen, W. Nerdal, Chlorpromazine interaction with
phosphatidylserines: a (13)C and (31)P solid-state NMR study, Biochim. Biophys.
Acta 1682 (2004) 28–37.
[28] H. Holmsen, C.A. Dangelmaier, Triﬂuoperazine enhances accumulation and
inhibits phosphohydrolysis of phosphatidate in thrombin-stimulated platelets,
Thromb. Haemost. 64 (1990) 307–311.
[29] V.M. Steen, O.B. Tysnes, H. Holmsen, Evidence for tight metabolic control of the
receptor-activated polyphosphoinositide cycle in human platelets, Biochem. J. 263
(1989) 621–624.
[30] O.B. Tysnes, V.M. Steen, K.W. Frolich, H. Holmsen, Evidence that chlorpromazine
and prostaglandin E1 but not neomycin interfere with the inositol phospholipid
metabolism in intact human platelets, FEBS Lett. 264 (1990) 33–36.
[31] A.J. Verhoeven, O.B. Tysnes, G.M. Aarbakke, C.A. Cook, H. Holmsen, Turnover of the
phosphomonoester groups of polyphosphoinositol lipids in unstimulated human
platelets, Eur. J. biochem. FEBS 166 (1987) 3–9.
[32] O.B. Tysnes, G.M. Aarbakke, A.J. Verhoeven, H. Holmsen, Thin-layer chromato-
graphy of polyphosphoinositides from platelet extracts: interference by an
unknown phospholipid, Thromb. Res. 40 (1985) 329–338.
[33] B. Lages, M.C. Scrutton, H. Holmsen, Studies on gel-ﬁltered human platelets:
isolation and characterization in amedium containing no added Ca2+,Mg2+, or K+,
J. lab. Clin. Med. 85 (1975) 811–825.
[34] H. Holmsen, C.A. Dangelmaier, H.K. Holmsen, Thrombin-induced platelet
responses differ in requirement for receptor occupancy. Evidence for tight
coupling of occupancy and compartmentalized phosphatidic acid formation,
J. Biol. Chem. 256 (1981) 9393–9396.
[35] A. Broniec, A.U. Gjerde, A.B. Olmheim, H. Holmsen, Triﬂuoperazine causes a
disturbance in glycerophospholipid monolayers containing phosphatidylserine (PS):
effects of pH, acyl unsaturation, and proportion of PS, Langmuir 23 (2007) 694–699.
[36] K. Nambu, H. Miyazaki, Y. Nakanishi, Y. Oh-e, Y. Matsunaga, M. Hashimoto,
Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins,
Biochem. Pharmacol. 36 (1987) 1715–1722.
[37] G. Theodoridis, Application of solid-phase microextraction in the investigation of
protein binding of pharmaceuticals, J. Chromatog. 830 (2006) 238–244.[38] R.K. Verbeeck, J.A. Cardinal, A.G. Hill, K.K. Midha, Binding of phenothiazine
neuroleptics to plasma proteins, Biochem. Pharmacol. 32 (1983) 2565–2570.
[39] D. Zhou, F. Li, Protein binding study of clozapine by capillary electrophoresis in the
frontal analysis mode, J. Pharmaceut. Biomed. Anal. 35 (2004) 879–885.
[40] S.R. Nahorski, K.W. Young, R.A. John Challiss, M.S. Nash, Visualizing phosphoinosi-
tide signalling in single neurons gets a green light, Trends Neurosci. 26 (2003)
444–452.
[41] V. Niggli, Regulation of protein activities by phosphoinositide phosphates, Ann.
Rev. Cell Dev. Biol. 21 (2005) 57–79.
[42] R.F. Irvine, Nuclear lipid signalling, Nat. Rev. 4 (2003) 349–360.
[43] J.R. Halstead, K. Jalink, N. Divecha, An emerging role for PtdIns(4,5)P2-mediated
signalling in human disease, Trends Pharmacol. Sci. 26 (2005) 654–660.
[44] E.S. Husebye, T. Flatmark, Phosphatidylinositol kinase of bovine adrenal
chromafﬁn granules: kinetic properties and inhibition by low concentrations of
Ca2+, Biochim. Biophys. Acta 968 (1988) 261–265.
[45] E.S. Husebye, T. Flatmark, Puriﬁcation and kinetic properties of a soluble pho-
sphatidylinositol-4-phosphate kinase of the bovine adrenal medulla with emphasis
on its inhibition by calcium ions, Biochim. Biophys. Acta 1010 (1989) 250–257.
[46] E. Quist, N. Satumtira, P. Powell, Regulation of polyphosphoinositide synthesis in
cardiac membranes, Arch. Biochem. Biophys. 271 (1989) 21–32.
[47] E.S. Husebye, A.J. Letcher, D.J. Lander, T. Flatmark, Puriﬁcation and kinetic
properties of a membrane-bound phosphatidylinositol kinase of the bovine
adrenal medulla, Biochim. Biophys. Acta 1042 (1990) 330–337.
[48] H. Wakatabe, T. Tsukahara, J. Ishigooka, S. Miura, Effects of chlorpromazine on
phosphatidylinositol turnover following thrombin stimulation of human platelets,
Biol. Psychiatry 29 (1991) 965–978.
[49] F. Hayashi, T. Amakawa, Calcium- and calmodulin-dependent phosphorylation of
diphosphoinositide in acetylcholine receptor-rich membranes from electroplax of
Narke japonica, J. Neurochem. 45 (1985) 124–131.
[50] N.E. Tooke, C.N. Hales, J.C. Hutton, Ca2+-sensitive phosphatidylinositol 4-
phosphate metabolism in a rat beta-cell tumour, Biochem. J. 219 (1984) 471–480.
[51] A. Jutila, T. Soderlund, A.L. Pakkanen, M. Huttunen, P.K. Kinnunen, Comparison of
the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral
heterogeneity, Chem. Phys. Lipids 112 (2001) 151–163.
[52] C.R. Oliveira, M.C. Lima, C.A. Carvalho, J.E. Leysen, A.P. Carvalho, Partition
coefﬁcients of dopamine antagonists in brain membranes and liposomes,
Biochem. Pharmacol. 38 (1989) 2113–2120.
[53] C.M. Palmeira, C.R. Oliveira, Partitioning and membrane disordering effects of
dopamine antagonists: inﬂuence of lipid peroxidation, temperature, and drug
concentration, Arch. Biochem. Biophys. 295 (1992) 161–171.
[54] C. Tessier, P. Nuss, G. Staneva, C. Wolf, Modiﬁcation of membrane heterogeneity by
antipsychotic drugs: an X-ray diffraction comparative study, J. Colloid Interface Sci.
320 (2008) 469–475.
[55] M.M. Ho, D.J. Scales, G. Inesi, The effect of triﬂuoroperazine on the sarcoplasmic
reticulum membrane, Biochim. Biophys. Acta 730 (1983) 64–70.
[56] R.I. MacDonald, Triﬂuoperazine inhibits Sendai virus-induced hemolysis, Biochim.
Biophys. Acta 856 (1986) 337–347.
[57] S.V. Malheiros, E. de Paula, N.C. Meirelles, Contribution of triﬂuoperazine/lipid
ratio and drug ionization to hemolysis, Biochim. Biophys. Acta 1373 (1998)
332–340.
[58] S.V. Malheiros, N.C. Meirelles, E. de Paula, Pathways involved in triﬂuoperazine-,
dibucaine- and praziquantel-induced hemolysis, Biophys. Chem. 83 (2000)
89–100.
[59] P.F. Pavlov, E. Glaser, Inhibition of protein import intomitochondria by amphiphilic
cations: potential targets and mechanism of action, Biochem. Biophys. Res.
Commun. 252 (1998) 84–91.
[60] C. Song, H. Holmsen, W. Nerdal, Existence of lipid microdomains in bilayer of
dipalmitoyl phosphatidylcholine (DPPC) and 1-stearoyl-2-docosahexenoyl phos-
phatidylserine (SDPS) and their perturbation by chlorpromazine: a 13C and 31P
solid-state NMR study, Biophys. Chem. 120 (2006) 178–187.
[61] A. Varnier Agasoster, H. Holmsen, Chlorpromazine associates with phosphatidyl-
serines to cause an increase in the lipid's own interfacial molecular area—role of
the fatty acyl composition, Biophys. Chem. 91 (2001) 37–47.
[62] S. Takegami, K. Kitamura, T. Kitade, M. Takashima, M. Ito, E. Nakagawa, M. Sone, R.
Sumitani, Y. Yasuda, Effects of phosphatidylserine and phosphatidylethanolamine
content on partitioning of triﬂupromazine and chlorpromazine between phos-
phatidylcholine-aminophospholipid bilayer vesicles and water studied by second-
derivative spectrophotometry, Chem. Pharm. Bull. 53 (2005) 147–150.
[63] M. Pickholz, O.N. Oliveira Jr., M.S. Skaf, Molecular dynamics simulations of neutral
chlorpromazine in zwitterionic phospholipid monolayers, J. Phys. Chem. 110
(2006) 8804–8814.
[64] M. Pickholz, O.N. Oliveira Jr., M.S. Skaf, Interactions of chlorpromazine with
phospholipid monolayers: effects of the ionization state of the drug, Biophys.
Chem. 125 (2007) 425–434.
[65] A.B. Sarmento, M.C. de Lima, C.R. Oliveira, Partition of dopamine antagonists into
synthetic lipid bilayers: the effect of membrane structure and composition,
J. Pharm. Pharmacol. 45 (1993) 601–605.
[66] S. Axelsson, S. Hagg, A.C. Eriksson, T.L. Lindahl, P.A. Whiss, In vitro effects of
antipsychotics on human platelet adhesion and aggregation and plasma coagula-
tion, Clin. Exp. Pharmacol. Physiol. 34 (2007) 775–780.
[67] G. Anfossi, M. Trovati, E. Mularoni, P. Massucco, F. Cavalot, L. Mattiello, G.
Emanuelli, Phenothiazine compounds enhance phentolamine effects on platelet
aggregation and thromboxane B2 production, Arch. Int. Pharmacodyn. Ther. 307
(1990) 142–161.
[68] T.K. Gartner, D.A. Walz, TFP inhibits the expression of the endogenous platelet
lectin and secretion of alpha-granules, Thromb. Res. 29 (1983) 63–74.
